RegenXBio Holds 2025 Annual Stockholders Meeting

An announcement from RegenXBio ( (RGNX) ) is now available.

At REGENXBIO Inc.’s 2025 Annual Meeting of Stockholders held on May 30, 2025, several key proposals were voted on. Four individuals were elected as Class I directors to serve until 2028, and PricewaterhouseCoopers LLP was ratified as the independent public accounting firm for the year. Additionally, stockholders approved the executive compensation plan and decided to hold annual advisory votes on this matter. The 2025 Equity Incentive Plan was also approved.

The most recent analyst rating on (RGNX) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.

Spark’s Take on RGNX Stock

According to Spark, TipRanks’ AI Analyst, RGNX is a Neutral.

RegenXBio’s overall stock score reflects a blend of promising strategic initiatives and ongoing financial challenges. Technical indicators and corporate events are positive, highlighting potential future growth, but persistent net losses and valuation concerns weigh on the score. The earnings call provided strong guidance, mitigating some financial risks.

To see Spark’s full report on RGNX stock, click here.

More about RegenXBio

REGENXBIO Inc. operates in the biotechnology industry, focusing on the development of gene therapy products. The company is known for its NAV Technology Platform, which is used to develop treatments for a range of genetic disorders.

Average Trading Volume: 1,137,799

Technical Sentiment Signal: Sell

Current Market Cap: $519.2M

Learn more about RGNX stock on TipRanks’ Stock Analysis page.